



**FOR IMMEDIATE RELEASE**

## **Compugen to Present at Single Cell Genomics 2023 Meeting**

HOLON, ISRAEL, October 03, 2023 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.

The data will highlight the computational characterization of PVRIG's expression providing a deeper understanding of its unique biology and rationale for targeting PVRIG in tumors, typically those not responding to immunotherapy.

### **Poster presentation details:**

**Poster Title:** Elucidating the Mechanism of Action of the Novel Immune Checkpoint PVRIG: Insights from Single-Cell and High-Resolution Spatial Transcriptomics

**Poster number:** P1.65

**Presenter:** Roy Granit, Ph.D., Head of Computational Discovery, Compugen Ltd.

**Date:** Monday, October 9, 2023

The poster will be available on the publications section of Compugen's website, [www.cgen.com](http://www.cgen.com), following presentation.

### **About Compugen**

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2 development by AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced program, COM503 is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment.

Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

**Company contact:**

Yvonne Naughton, Ph.D.

Head of Investor Relations and Corporate Communications

Email: [ir@cgen.com](mailto:ir@cgen.com)

Tel: +1 (628) 241-0071